NOTE: It’s easy! Submit your order and Pet’s First Choice will verify your pet’s prescription with your veterinarian. Please allow 24-48 hours for this validation.
Laverdia-CA1 Tablets
Starting at $150.99
Description
Laverdia-CA1® (verdinexor) is the first FDA conditionally approved oral medication for the treatment of canine lymphoma, one of the most common cancers in dogs. This groundbreaking, vet-prescribed cancer treatment works by blocking proteins that allow cancer cells to grow and spread, helping to slow disease progression and improve quality of life.
Laverdia-CA1 offers a convenient, at-home oral tablet, giving pet parents a non-invasive option that doesn’t require hospital-based chemotherapy. It’s designed for dogs diagnosed with intermediate to high-grade lymphoma and may be used as a primary or adjunct therapy under veterinary guidance.
-
Treats Canine Lymphoma – First oral tablet approved for treating lymphoma in dogs.
-
Non-Invasive Option – No IV or hospital visits; can be given at home.
-
Slows Disease Progression – Helps delay cancer advancement and manage symptoms.
-
Supports Quality of Life – May improve energy, appetite, and comfort during treatment.
-
Conditionally FDA-Approved – Backed by research and available through licensed veterinarians.
-
Convenient Oral Dosing – Simple tablet form is easier on dogs and caregivers than traditional chemotherapy.
-
Use as Primary or Adjunct Therapy – Can be used alone or alongside other treatments as advised by your vet.
Additional information
| Quantity | 50ct |
|---|---|
| Dosage | 150mg, 2.5mg, 10mg, 50mg |
